S&P 500   4,550.58 (-0.09%)
DOW   35,430.42 (+0.04%)
QQQ   389.81 (-0.10%)
AAPL   189.37 (-0.54%)
MSFT   378.85 (-1.01%)
META   332.20 (-2.00%)
GOOGL   134.99 (-1.61%)
AMZN   146.32 (-0.48%)
TSLA   244.14 (-1.05%)
NVDA   481.40 (+0.67%)
NIO   7.18 (-0.42%)
BABA   74.67 (-2.70%)
AMD   123.85 (+1.51%)
T   16.30 (+0.74%)
F   10.59 (+2.12%)
MU   76.69 (+0.75%)
CGC   0.56 (+3.57%)
GE   118.86 (+0.01%)
DIS   92.50 (+0.00%)
AMC   7.17 (+7.01%)
PFE   30.08 (+1.31%)
PYPL   57.97 (-0.86%)
XOM   102.34 (-1.50%)
S&P 500   4,550.58 (-0.09%)
DOW   35,430.42 (+0.04%)
QQQ   389.81 (-0.10%)
AAPL   189.37 (-0.54%)
MSFT   378.85 (-1.01%)
META   332.20 (-2.00%)
GOOGL   134.99 (-1.61%)
AMZN   146.32 (-0.48%)
TSLA   244.14 (-1.05%)
NVDA   481.40 (+0.67%)
NIO   7.18 (-0.42%)
BABA   74.67 (-2.70%)
AMD   123.85 (+1.51%)
T   16.30 (+0.74%)
F   10.59 (+2.12%)
MU   76.69 (+0.75%)
CGC   0.56 (+3.57%)
GE   118.86 (+0.01%)
DIS   92.50 (+0.00%)
AMC   7.17 (+7.01%)
PFE   30.08 (+1.31%)
PYPL   57.97 (-0.86%)
XOM   102.34 (-1.50%)
S&P 500   4,550.58 (-0.09%)
DOW   35,430.42 (+0.04%)
QQQ   389.81 (-0.10%)
AAPL   189.37 (-0.54%)
MSFT   378.85 (-1.01%)
META   332.20 (-2.00%)
GOOGL   134.99 (-1.61%)
AMZN   146.32 (-0.48%)
TSLA   244.14 (-1.05%)
NVDA   481.40 (+0.67%)
NIO   7.18 (-0.42%)
BABA   74.67 (-2.70%)
AMD   123.85 (+1.51%)
T   16.30 (+0.74%)
F   10.59 (+2.12%)
MU   76.69 (+0.75%)
CGC   0.56 (+3.57%)
GE   118.86 (+0.01%)
DIS   92.50 (+0.00%)
AMC   7.17 (+7.01%)
PFE   30.08 (+1.31%)
PYPL   57.97 (-0.86%)
XOM   102.34 (-1.50%)
S&P 500   4,550.58 (-0.09%)
DOW   35,430.42 (+0.04%)
QQQ   389.81 (-0.10%)
AAPL   189.37 (-0.54%)
MSFT   378.85 (-1.01%)
META   332.20 (-2.00%)
GOOGL   134.99 (-1.61%)
AMZN   146.32 (-0.48%)
TSLA   244.14 (-1.05%)
NVDA   481.40 (+0.67%)
NIO   7.18 (-0.42%)
BABA   74.67 (-2.70%)
AMD   123.85 (+1.51%)
T   16.30 (+0.74%)
F   10.59 (+2.12%)
MU   76.69 (+0.75%)
CGC   0.56 (+3.57%)
GE   118.86 (+0.01%)
DIS   92.50 (+0.00%)
AMC   7.17 (+7.01%)
PFE   30.08 (+1.31%)
PYPL   57.97 (-0.86%)
XOM   102.34 (-1.50%)

Alpha Tau Medical Stock Price, News & Analysis (NASDAQ:DRTS)

$3.20
-0.01 (-0.31%)
(As of 05:28 PM ET)
Compare
Today's Range
$3.08
$3.33
50-Day Range
$2.79
$3.89
52-Week Range
$2.75
$5.95
Volume
42,863 shs
Average Volume
55,661 shs
Market Capitalization
$221.98 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.33

Alpha Tau Medical MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
316.7% Upside
$13.33 Price Target
Short Interest
Healthy
0.17% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.96mentions of Alpha Tau Medical in the last 14 days
Based on 7 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.46) to ($0.54) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.21 out of 5 stars

Medical Sector

438th out of 949 stocks

Surgical & Medical Instruments Industry

57th out of 95 stocks


DRTS stock logo

About Alpha Tau Medical Stock (NASDAQ:DRTS)

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.

DRTS Stock Price History

DRTS Stock News Headlines

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Alpha Tau Medical's (DRTS) "Buy" Rating Reaffirmed at HC Wainwright
Alpha Tau Medical (NASDAQ:DRTS) Price Target Cut to $8.00
Analyst Ratings for Alpha Tau Medical
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Alpha Tau Medical GAAP EPS of $0.31
Recap: Alpha Tau Medical Q1 Earnings
Alpha Tau Medical Ltd (DRTS) Receives a Buy from H.C. Wainwright
See More Headlines
Receive DRTS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alpha Tau Medical and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/16/2023
Today
11/29/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/14/2024

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:DRTS
Fax
N/A
Employees
94
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$13.33
High Stock Price Target
$23.00
Low Stock Price Target
$8.00
Potential Upside/Downside
+315.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-33,760,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.30 per share

Miscellaneous

Free Float
41,971,000
Market Cap
$222.68 million
Optionable
Not Optionable
Beta
0.93
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Uzi Sofer (Age 53)
    CEO & Chairman
    Comp: $1.58M
  • Mr. Raphi Levy (Age 38)
    Chief Financial Officer
    Comp: $1.24M
  • Mr. Amnon Gat (Age 48)
    Chief Operations Officer
    Comp: $497k
  • Mr. Ronen Segal (Age 50)
    Chief Technology Officer
    Comp: $380k
  • Dr. Robert B. Den M.D. (Age 44)
    Chief Medical Officer & Member of Scientific Advisory Board
    Comp: $565k
  • Prof. Yona Keisari (Age 76)
    Chief Scientific Officer & Member of Scientific Advisory board
  • Ms. Rebecca Becker
    Vice President of legal
  • Mr. Peter M. Melnyk (Age 61)
    Chief Commercial Officer
  • Prof. Itzhak Kelson (Age 83)
    Chief Physics Officer & Member of Scientific Advisory Board
  • Ms. Yael Zeiger (Age 40)
    Corporate Controller














DRTS Stock Analysis - Frequently Asked Questions

Should I buy or sell Alpha Tau Medical stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Alpha Tau Medical in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" DRTS shares.
View DRTS analyst ratings
or view top-rated stocks.

What is Alpha Tau Medical's stock price target for 2024?

3 equities research analysts have issued 1 year price targets for Alpha Tau Medical's shares. Their DRTS share price targets range from $8.00 to $23.00. On average, they anticipate the company's stock price to reach $13.33 in the next year. This suggests a possible upside of 316.7% from the stock's current price.
View analysts price targets for DRTS
or view top-rated stocks among Wall Street analysts.

How have DRTS shares performed in 2023?

Alpha Tau Medical's stock was trading at $3.18 on January 1st, 2023. Since then, DRTS shares have increased by 0.6% and is now trading at $3.20.
View the best growth stocks for 2023 here
.

Are investors shorting Alpha Tau Medical?

Alpha Tau Medical saw a decrease in short interest in November. As of November 15th, there was short interest totaling 65,100 shares, a decrease of 8.2% from the October 31st total of 70,900 shares. Based on an average daily trading volume, of 26,500 shares, the short-interest ratio is presently 2.5 days. Currently, 0.2% of the shares of the company are short sold.
View Alpha Tau Medical's Short Interest
.

When is Alpha Tau Medical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 14th 2024.
View our DRTS earnings forecast
.

How were Alpha Tau Medical's earnings last quarter?

Alpha Tau Medical Ltd. (NASDAQ:DRTS) issued its quarterly earnings results on Thursday, November, 16th. The company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.12) by $0.05.

Who are Alpha Tau Medical's major shareholders?

Alpha Tau Medical's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Hoylecohen LLC (0.39%), Levin Capital Strategies L.P. (0.12%) and Citigroup Inc. (0.02%).

How do I buy shares of Alpha Tau Medical?

Shares of DRTS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:DRTS) was last updated on 11/29/2023 by MarketBeat.com Staff

My Account -